FGFR1 and breast carcinoma: Co-amplification of 4EBP1 and FGFR1 was significantly correlated with poor survival in breast cancer with a median survival of 94 months in 4EBP1 and FGFR1 amplified versus 115 months in non-amplified cases (Figure 1D).